MedTrace Logo

DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI

NCT02070731 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2015-08-27

No results posted yet for this study

Summary

A randomized evaluation of the TriGuard™ HDH embolic deflection device during transcatheter aortic valve implantation.

Conditions

  • Aortic Valve Stenosis

Interventions

DEVICE

TriGuard HDH

TAVI with the TriGuard HDH embolic deflection device

Sponsors & Collaborators

  • Keystone Heart

    lead INDUSTRY

Principal Investigators

  • Andreas Baumbach, Md. · Bristol Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-03-31
Completion
2015-04-30

Countries

  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070731 on ClinicalTrials.gov